首页> 外文期刊>American Journal of Physiology >Adenosine AA and AB receptors are both required for adenosine A receptor-mediated cardioprotection.
【24h】

Adenosine AA and AB receptors are both required for adenosine A receptor-mediated cardioprotection.

机译:腺苷A受体和A受体都是腺苷A受体介导的心脏保护作用所必需的。

获取原文
获取原文并翻译 | 示例
           

摘要

All four adenosine receptor subtypes have been shown to play a role in cardioprotection, and there is evidence that all four subtypes may be expressed in cardiomyocytes. There is also increasing evidence that optimal adenosine cardioprotection requires the activation of more than one receptor subtype. The purpose of this study was to determine whether adenosine A(2A) and/or A(2B) receptors modulate adenosine A(1) receptor-mediated cardioprotection. Isolated perfused hearts of wild-type (WT), A(2A) knockout (KO), and A(2B)KO mice, perfused at constant pressure and constant heart rate, underwent 30 min of global ischemia and 60 min of reperfusion. The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA; 200 nM) was administrated 10 min before ischemia and for the first 10 min of reperfusion. Treatment with CHA significantly improved postischemic left ventricular developed pressure (74 +/- 4% vs. 44 +/- 4% of preischemic left ventricular developed pressure at 60 min of reperfusion) and reduced infarct size (30 +/- 2% with CHA vs. 52 +/- 5% in control) in WT hearts, effects that were blocked by the A(1) antagonist 8-cyclopentyl-1,3-dipropylxanthine (100 nM). Treatments with the A(2A) receptor agonist CGS-21680 (200 nM) and the A(2B) agonist BAY 60-6583 (200 nM) did not exert any beneficial effects. Deletion of adenosine A(2A) or A(2B) receptor subtypes did not alter ischemia-reperfusion injury, but CHA failed to exert a cardioprotective effect in hearts of mice from either KO group. These findings indicate that both adenosine A(2A) and A(2B) receptors are required for adenosine A(1) receptor-mediated cardioprotection, implicating a role for interactions among receptor subtypes.
机译:已经显示所有四种腺苷受体亚型都在心脏保护中起作用,并且有证据表明所有四种亚型都可以在心肌细胞中表达。越来越多的证据表明,最佳的腺苷心脏保护作用需要激活一种以上的受体亚型。这项研究的目的是确定是否腺苷A(2A)和/或A(2B)受体调节腺苷A(1)受体介导的心脏保护作用。在恒定压力和恒定心率下灌注的野生型(WT),A(2A)敲除(KO)和A(2B)KO小鼠的离体灌注心脏经历了30分钟的整体缺血和60分钟的再灌注。在缺血前10分钟和再灌注的前10分钟给予腺苷A(1)受体激动剂N(6)-环己基腺苷(CHA; 200 nM)。 CHA治疗可显着改善缺血性左心室发育压力(74 +/- 4%vs.缺血再灌注前60分钟时缺血性左心室发育压力的44 +/- 4%),并减少梗死面积(CHA为30 +/- 2%与WT心脏中的对照组的52 +/- 5%相比)受到A(1)拮抗剂8-环戊基-1,3-二丙基黄嘌呤(100 nM)阻断的作用。使用A(2A)受体激动剂CGS-21680(200 nM)和A(2B)激动剂BAY 60-6583(200 nM)的治疗没有产生任何有益效果。腺苷A(2A)或A(2B)受体亚型的删除并没有改变缺血-再灌注损伤,但CHA未能在任一KO组的小鼠心脏中发挥心脏保护作用。这些发现表明,腺苷A(1)受体介导的心脏保护都需要腺苷A(2A)和A(2B)受体,这暗示了受体亚型之间相互作用的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号